FORT LAUDERDALE, Fla., Dec. 7, 2004 (PRIMEZONE) -- Sunwin International Neutraceuticals, Inc. (OTCBB:SUWN) announced today that Michael Norman, Founder and Publisher of the Economic Contrarian Update issued a research report on the company in his daily newsletter. Here are some of the report's conclusions:
-- "Sunwin is an example of a company with high quality standards
that could be a select provider of (traditional Chinese
medicinal) products to the Chinese domestic market as well as the
export market."
-- "Sunwin also produces stevioside, which is a beetroot based
natural sweetener that has no carbs, thus tapping into the low-
carb craze."
-- "In 2002, worldwide demand for stevioside, the key ingredient for
beetroot based natural sweeteners, exceeded 1,200 tons and China
accounted for 80 percent of worldwide supply of which 200 tons,
or 16 percent of worldwide production, was produced by SUWN."
-- "Sunwin may be well positioned to capitalize on a major policy
shift that is now under way in China."
-- "Goldman Sachs predicts that the People's Bank of China may adjust
the RMB exchange at anytime. If this were to happen, it could
have a material, positive effect on the results of Sunwin."
(Investors can access full report here: www.contrarian-update.com/free/suwn.htm or www.sunwin.biz)
About Sunwin International Neutraceuticals, Inc.
Sunwin International Neutraceuticals, Inc. ("Sunwin") is engaged in the areas of essential traditional Chinese medicine, 100% organic herbal medicine, nutraceutical products, natural sweetener (beet sugar), and animal medicine prepared from 100% organic herbal ingredients. Sunwin International Neutraceuticals, Inc. is doing business in China through its subsidiary, Shandong Qufu Natural Green Engineering Company, Limited ("Qufu"). As an industry leader in agricultural processing, Sunwin has built an integrated global firm with the sourcing and production capabilities to meet the needs of consumers throughout the world. Sunwin also makes such value-added products as specialty veterinary food ingredients and specialty feed ingredients. The Sunwin family works closely with consumer to provide a quality, value, and a hybrid mix of agricultural products and services that meet growing demand. In 2002, Sunwin was recognized as one of the first 2,000 state-level companies that China authorized as the most important innovative high-tech pioneer businesses by the Chinese central government. In 2002, Sunwin was awarded as one of 2002 state-level biological product manufacturers in China. In 2003, Sunwin ranked as one of the top 50 companies of China's Animal Related Health Care Product Pharmaceutical Industry. In 2003, Sunwin received an award as one of Shandong Top-Ten Innovative, High-Tech Businesses by the Province Government of Shandong. For more information about Sunwin, please visit http://www.sunwin.biz.
About The Economic Contrarian Update
The Economic Contrarian Update is a global, macroeconomic perspective of investment trends in stocks, bonds, currencies and commodity markets. The publication strives to examine arguments against widely followed themes, with the idea that once a major investment idea is known and fully discounted; there are both new risks and new opportunities. Publisher Michael Norman believes that long-term success is built upon questioning the so-called prevailing wisdom of Wall Street, which tends to be very self-centered and prone to one way thinking. To be a successful investor, it is imperative to think and behave independently, and not being limited to any one, particular market. Perspective is extremely important, as is the concept of value and timing. This is what Mr. Norman strives to bring to investors in his writings and in the writings of others contributors featured on this site. The Economic Contrarian Update has some of the top banks, investment banks, brokerage firms, hedge funds and traders as clients. For more information, please visit http://www.contrarian-update.com
Economic Contrarian Update received $2,500 from a third party to write and distribute Sunwin International Neutraceuticals, Inc. report. The analyst hereby certifies that he does not own any share in Sunwin International Neutraceuticals, Inc. Moreover, Economic Contrarian Update and Michael Norman do not have any investment banking relationship with Sunwin International Neutraceuticals, Inc. Reprinting, reproduction, or copying of this report or any material contained herein is strictly prohibited.
Safe Harbor Statement
Certain of the statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "should," "could," "would," "may" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited financial resources, domestic or global economic conditions -- especially those relating to China, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws, restrictions and regulations on doing business in a foreign country, in particular China, and conditions of equity markets. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.